---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038366"
form_type: "8-K"
ticker: "VYCO"
cik: "0001424768"
company_name: "VYCOR MEDICAL INC"
filed_at: "2026-08-14T20:13:30+00:00"
generated_at: "2026-08-14T20:20:52.072985+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vycor Medical Q2 revenue down 16% to $418K; operating profit falls to $6.9K

## Summary
- Q2 2026 revenue $418,264, down 16% YoY; Vycor Medical division down 17% to $401,224 on international weakness.
- Q2 operating profit $6,851 vs $51,146 in 2025; non-GAAP operating profit $22,952 vs $85,712.
- Six-month revenue $876,804, down 6%; operating profit $52,659 vs $38,340 in 2025.
- NovaVision in development: Q2 revenue $17,040, up 17% YoY; six-month $35,139, up 8%.
- Three new peer-reviewed VBAS studies published in 2026; total now 53 peer-reviewed papers.

## SEC filing metadata
- accession: 0001493152-26-038366
- form_type: 8-K
- ticker: VYCO
- cik: 0001424768
- company_name: VYCOR MEDICAL INC
- filed_at: 2026-08-14T20:13:30+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1424768/000149315226038366/0001493152-26-038366-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1424768/000149315226038366/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038366
- JSON: https://secwatch.observer/filing/0001493152-26-038366.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038366.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.